Connection

JEFFREY ROSEN to Antineoplastic Agents

This is a "connection" page, showing publications JEFFREY ROSEN has written about Antineoplastic Agents.
Connection Strength

0.456
  1. Targeting eIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancer. J Clin Invest. 2023 12 15; 133(24).
    View in: PubMed
    Score: 0.186
  2. Morphological screening of mesenchymal mammary tumor organoids to identify drugs that reverse epithelial-mesenchymal transition. Nat Commun. 2021 07 12; 12(1):4262.
    View in: PubMed
    Score: 0.157
  3. CREB-binding protein/P300 bromodomain inhibition reduces neutrophil accumulation and activates antitumor immunity in triple-negative breast cancer. JCI Insight. 2024 Sep 17; 9(20).
    View in: PubMed
    Score: 0.049
  4. The MMTV-Wnt1 murine model produces two phenotypically distinct subtypes of mammary tumors with unique therapeutic responses to an EGFR inhibitor. Dis Model Mech. 2019 07 05; 12(7).
    View in: PubMed
    Score: 0.034
  5. Epithelial-mesenchymal transition (EMT) in tumor-initiating cells and its clinical implications in breast cancer. J Mammary Gland Biol Neoplasia. 2010 Jun; 15(2):253-60.
    View in: PubMed
    Score: 0.018
  6. Chk1 versus Cdc25: chking one's levels of cellular proliferation. Cell Cycle. 2004 Nov; 3(11):1355-7.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.